Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D P Benziger

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Clinical Pharmacology and Therapeutics|January 1, 1996
Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodoneR F Kaiko, D P Benziger, R D Fitzmartin, et al.
Archives Internationales De Pharmacodynamie Et De Therapie|November 1, 1978
Absorption and disposition of N-(1, 1-dimethylethyl)-N'-[2-(4-pyridinyl)-4-pyrimidinyl]urea in rats and dogsJ F Baker, A F Jensen, B W Chalecki, et al.
Clinical Pharmacology and Therapeutics|December 1, 1986
Effect of the acetylator phenotype on amrinone pharmacokineticsR A Hamilton, S F Kowalsky, E M Wright, et al.
International Journal of Clinical Practice|July 30, 2008
A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteriaD E Katz, K C Lindfield, J N Steenbergen, et al.
Circulation|March 1, 1986
Pharmacokinetics of the bipyridines amrinone and milrinoneJ Edelson, R Stroshane, D P Benziger, et al.
Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology|May 1, 1992
Subchronic oral and intravenous (i.v.) safety evaluation and pharmacokinetics in rats and dogs of ipazilide fumarate (Win 54, 177-4), an antiarrhythmic agentY Greener, B A Mayes, T A Barbolt, et al.
The Journal of Clinical Endocrinology and Metabolism|October 5, 2002
The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adultsD M Cook, B M K Biller, M L Vance, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Clinical Pharmacology and Therapeutics|January 1, 1996
Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodoneR F Kaiko, D P Benziger, R D Fitzmartin, et al.
Archives Internationales De Pharmacodynamie Et De Therapie|November 1, 1978
Absorption and disposition of N-(1, 1-dimethylethyl)-N'-[2-(4-pyridinyl)-4-pyrimidinyl]urea in rats and dogsJ F Baker, A F Jensen, B W Chalecki, et al.
Clinical Pharmacology and Therapeutics|December 1, 1986
Effect of the acetylator phenotype on amrinone pharmacokineticsR A Hamilton, S F Kowalsky, E M Wright, et al.
International Journal of Clinical Practice|July 30, 2008
A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteriaD E Katz, K C Lindfield, J N Steenbergen, et al.
Circulation|March 1, 1986
Pharmacokinetics of the bipyridines amrinone and milrinoneJ Edelson, R Stroshane, D P Benziger, et al.
Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology|May 1, 1992
Subchronic oral and intravenous (i.v.) safety evaluation and pharmacokinetics in rats and dogs of ipazilide fumarate (Win 54, 177-4), an antiarrhythmic agentY Greener, B A Mayes, T A Barbolt, et al.
The Journal of Clinical Endocrinology and Metabolism|October 5, 2002
The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adultsD M Cook, B M K Biller, M L Vance, et al.
Pageof 3